Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Chin Med J (Engl). 2013;126(17):3356-9.
Vitamin D status in relation to pancreatic cancer risks is still inconsistent. This study was performed to evaluate the association between vitamin D status and risk of pancreatic cancer using a meta-analysis approach.
A systemic review of all relevant literature in English was performed by searching Pubmed, Web of Science and Embase to identify eligible studies from the earliest available date to April 1, 2012. The search terms "vitamin D", "25-hydroxyvitamin D", "pancreatic cancer" or "pancreatic neoplasms" were used to retrieve relevant papers. Inclusion criteria were: (1) the exposure of interest was intake of vitamin D or blood levels of vitamin D; (2) the outcome of interest was pancreatic cancer; (3) data on high and low intake or blood vitamin D in cases and controls were available; (4) odds ratio (OR) estimates with 95% confidence interval (CI) were provided; (5) primary epidemiological data were provided reporting pancreatic cancer incidence. The combined OR values and their 95% CIs were calculated via a meta-analysis. The potential presence of publication bias was estimated using Egger's regression asymmetry test.
Nine studies with a total of 1 206 011 participants met the inclusion criteria. The test for heterogeneity showed there were significant differences among the included studies (I(2)=70.9%, P=0.001), so a randomized-effects model was used in the meta-analysis. The pooled OR of pancreatic cancer for the highest versus the lowest categories of vitamin D level was 1.14 (95% CI 0.896-1.451), and the Z-score for the overall effect was 1.06 (P=0.288), showing that there was no significant association between vitamin D levels and the risk of pancreatic cancer. Egger's test indicated there was a low possibility of publication bias in this study (P=0.348).
Dietary vitamin D or circulating concentrations of 25-hydroxyvitamin D are not associated with the risk of pancreatic cancer based on evidence from currently published studies.
维生素 D 状态与胰腺癌风险的关系仍不一致。本研究通过荟萃分析的方法，评估维生素 D 状态与胰腺癌风险之间的关系。
通过检索 Pubmed、Web of Science 和 Embase，检索从最早可用日期到 2012 年 4 月 1 日的所有相关文献，以评估英文文献中的所有相关文献。使用“维生素 D”、“25-羟维生素 D”、“胰腺癌”或“胰腺肿瘤”等检索词检索相关文献。纳入标准为：（1）暴露因素为维生素 D 摄入或血液中维生素 D 水平；（2）结局因素为胰腺癌；（3）病例对照中存在维生素 D 摄入或血液维生素 D 水平高低的数据；（4）提供比值比（OR）估计值及其 95%置信区间（CI）；（5）提供报告胰腺癌发病率的初级流行病学数据。通过荟萃分析计算合并 OR 值及其 95%CI。采用 Egger 回归不对称检验估计潜在的发表偏倚。
共有 9 项研究，总计 1206011 名参与者符合纳入标准。异质性检验显示，纳入的研究之间存在显著差异（I2=70.9%，P=0.001），因此在荟萃分析中使用随机效应模型。维生素 D 水平最高与最低组之间胰腺癌的合并 OR 为 1.14（95%CI 0.896-1.451），总体效应的 Z 分数为 1.06（P=0.288），表明维生素 D 水平与胰腺癌风险之间无显著相关性。Egger 检验表明，本研究中发表偏倚的可能性较低（P=0.348）。
根据目前发表的研究结果，饮食维生素 D 或 25-羟维生素 D 的循环浓度与胰腺癌风险无关。
